Cancer Research Meeting Calendar  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 3838-3842, July 1, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kramer, D. L.
Right arrow Articles by Sufrin, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kramer, D. L.
Right arrow Articles by Sufrin, J. R.

Combined Modulation of S-Adenosylmethionine Biosynthesis and S-Adenosylhomocysteine Metabolism Enhances Inhibition of Nucleic Acid Methylation and L1210 Cell Growth1

Debora L. Kramer, Carl W. Porter, Ronald T. Borchardt and Janice R. Sufrin2

Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263 [D. L. K., C. W. P., J. R. S.], and Departments of Pharmaceutical and Medicinal Chemistry, University of Kansas, Lawrence, Kansas 66045 [R. T. B.]

Biochemical modulation of methylation processes can be accomplished by agents which either reduce pools of S-adenosylmethionine (AdoMet), the principal methyl donor, or alternatively, which raise levels of S-adenosylhomocysteine (AdoHcy), a potent product inhibitor of methyltransferase reactions. Both strategies have apparent limitations arising from their direct interference with only one determinant of the intracellular AdoHcy/AdoMet ratio, a parameter proposed to be indicative of methylation inhibition. The biological consequences of maximally altering this ratio have been examined by the combined use of an inhibitor of AdoMet synthetase, L-2-amino-4-methoxy-cis-but-3-enoic acid (L-cisAMB), with inhibitors of AdoHcy hydrolase, 9-(trans-2',trans-3'-dihydroxycyclopent-4'-enyl)adenine (DHCA) and neplanocin A. At concentrations which inhibited growth of L1210 cells by 50% at 48 h, L-cisAMB alone rapidly depleted AdoMet pools, while neplanocin A or DHCA alone led to an accumulation of AdoHcy. When L-cisAMB was combined with either neplanocin A or DHCA, AdoHcy increased and, concomitantly, AdoMet pools decreased. The resultant AdoHcy/AdoMet ratios for up to 48 h ranged from 2.2 to 3.6—a value 4-fold greater than those achieved with neplanocin A or DHCA alone. This elevation in the AdoHcy/AdoMet ratio was accompanied by marked and sustained interference with DNA and RNA methylation and with a near-total inhibition of cell growth for a period of 24 to 96 h. Thus, the combined treatment with these two types of mechanistically different methylation inhibitors resulted in significantly enhanced interference with nucleic acid methylation and cell growth, both of which correlated directly with unprecedented increases in the AdoHcy/AdoMet ratio. This approach may have therapeutic implications in antiviral and/or antitumor strategies targeting methylation.

1 This work was supported by National Cancer Institute Grants CA-13038 and CA-24538 and National Institute of General Medical Sciences Grant GM-29332.

2 To whom request for reprints should be addressed, at Grace Cancer Drug Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.

Received 1/16/90. Revised 3/14/90.


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
R. Fux, D. Kloor, M. Hermes, T. Rock, B. Proksch, A. Grenz, U. Delabar, R. Bucheler, S. Igel, K. Morike, et al.
Effect of acute hyperhomocysteinemia on methylation potential of erythrocytes and on DNA methylation of lymphocytes in healthy male volunteers
Am J Physiol Renal Physiol, October 1, 2005; 289(4): F786 - F792.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
C. M. Stellrecht, L. S. Chen, and V. Gandhi
Inhibition of Oncogene Expression by RNA-Directed Agents
Am. Assoc. Cancer Res. Educ. Book, April 1, 2005; 2005(1): 338 - 343.
[Full Text] [PDF]


Home page
Cancer Res.Home page
K.-C. Kim, L. Geng, and S. Huang
Inactivation of a Histone Methyltransferase by Mutations in Human Cancers
Cancer Res., November 15, 2003; 63(22): 7619 - 7623.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
K. R Dimitrova, K. DeGroot, A. K Myers, and Y. D Kim
Estrogen and homocysteine
Cardiovasc Res, February 15, 2002; 53(3): 577 - 588.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
N. Radomski, C. Kaufmann, and C. Dreyer
Nuclear Accumulation of S-Adenosylhomocysteine Hydrolase in Transcriptionally Active Cells during Development of Xenopus laevis
Mol. Biol. Cell, December 1, 1999; 10(12): 4283 - 4298.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
L. Frostesjo, I. Holm, B. Grahn, A. W. Page, T. H. Bestor, and O. Heby
Interference with DNA Methyltransferase Activity and Genome Methylation during F9 Teratocarcinoma Stem Cell Differentiation Induced by Polyamine Depletion
J. Biol. Chem., February 14, 1997; 272(7): 4359 - 4366.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.